Similar articles

• Leflunomide abrogates accelerated heart allograft rejection in presensitized rats.

  Cheung A, Billingham M, Sherwood S, Brazelton T, Shorthouse R, Morris R. Cheung A, et al. Transplant Proc. 1997 Feb-Mar;29(1-2):1294-5. doi: 10.1016/s0041-1345(96)00524-6. Transplant Proc. 1997. PMID: 9123313 No abstract available.
• Triple drug treatment with cyclosporine, leflunomide and mycophenolate mofetil prevents rejection of pig islets transplanted into rats and primates.

  Wennberg L, Groth CG, Tibell A, Zhu S, Liu J, Rafael E, Söderlund J, Biberfeld P, Morris RE, Karlsson-Parra A, Korsgren O. Wennberg L, et al. Transplant Proc. 1997 Aug;29(5):2498. doi: 10.1016/s0041-1345(97)00463-6. Transplant Proc. 1997. PMID: 9270824 No abstract available.
• Leflunomide and its analogue X920715 synergize with cyclosporin A in preventing early graft failure and delaying graft rejection of xenogeneic islets in nonobese diabetic mice.

  Gysemans C, Waer M, Laureys J, Bouillon R, Mathieu C. Gysemans C, et al. Transplant Proc. 2001 May;33(3):2094-5. doi: 10.1016/s0041-1345(01)01961-3. Transplant Proc. 2001. PMID: 11377464 No abstract available.
• New immunosuppressive agents for organ transplantation.

  Waer M. Waer M. Acta Clin Belg. 1997;52(4):199-203. doi: 10.1080/17843286.1997.11718576. Acta Clin Belg. 1997. PMID: 9351290 Review. No abstract available.
• Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection.

  Bartlett RR, Dimitrijevic M, Mattar T, Zielinski T, Germann T, Rüde E, Thoenes GH, Küchle CC, Schorlemmer HU, Bremer E, et al. Bartlett RR, et al. Agents Actions. 1991 Jan;32(1-2):10-21. doi: 10.1007/BF01983301. Agents Actions. 1991. PMID: 2058454 Review.